[EXTERNAL QUALITY ASSESSMENT OF ANTI-TUBERCULOSIS DRUG SUSCEPTIBILITY TESTING FOR DIAGNOSING EXTENSIVELY
Abstract:
[Objective] The infectious disease control law has been amended in May 2015, and the category definition of Mycobacterium tuberculosis as infectious pathogen has been changed, following the definition of extensively drug-resistant M.tuberculosis (XDR-TB) by World Health Organization. To assess the diagnostic capacity of XDR-TB, we conducted an external quality assessment (EQA) for the anti-tuberculosis drug susceptibility testing (DST). [Method] A total of 10 M.tuberculosis strains with known drug susceptibility were sent to each participating laboratory. The drugs assessed were isoniazid (INH), rifampicin (RFP), streptomycin (SM), ethambutol (EB), levofloxacin (LVFX), and kanamycin (KM). DST was performed using each routine method(s), and the results were compared with the judicial diagnoses. The sensitivity, specificity, overall agreement (effi- ciency) and kappa coefficient were calculated for each drug tested. In addition, the diagnostic accuracy of multidrug-resis- tant M. tuberculosis (MDR-TB) and XDR-TB was assessed. [Results] A total of 88 institutes including 67 hospitals, 16 commercial laboratories, and 5 public health laboratories par- ticipated in the EQA. With 2 laboratories submitting 2 sets of results, a total of 90 independent data sets were analyzed. As for INH, RFP and LVFX, the efficiency was over 95%, but we found two strains each for SM, EB and KM with the efficiency less than 95%. Especially, strain 1 and strain 2 showed efficiency of 72.2% and 71.1% to SM, respectively. This error was mainly found in a certain test kit. If we consider the passing score as showing ≥95 % sensitivity and specificity both to INH and RFP, the diagnostic accuracy of MDR-TB was 92.2% (83/90) in this study. With the same criteria to INH, RFP, LVFX and KM, that of XDR-TB was 79.7% (63/79). [Discussion] The diagnostic capacity of XDR-TB was not sufficient in the current study. Good case management and pathogen control requires higher accuracy. The government may need to conduct a constant EQA and relevant remedial actions.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...


